{
    "organizations": [],
    "uuid": "bd46e4afa489d669de9b4a6bf8831ebdd86b1efe",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-kiadis-pharma-fy-net-loss-widens-t/brief-kiadis-pharma-fy-net-loss-widens-to-17-0-million-euros-idUSFWN1RP16N",
    "ord_in_thread": 0,
    "title": "BRIEF-Kiadis Pharma FY Net Loss Widens To 17.0 Million Euros",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 13 (Reuters) - Kiadis Pharma NV:\n* KIADIS PHARMA ANNOUNCES ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2017\n* SIGNIFICANTLY STRENGTHENED CASH POSITION; RAISED OVER EUR 60 MILLION IN EQUITY AND DEBT (GROSS, INCLUDING RAISE IN MARCH 2018)\n* FILED MARKETING AUTHORIZATION APPLICATION WITH EUROPEAN MEDICINES AGENCY FOR ATIR101 IN BLOOD CANCERS\n* FY NET LOSS EUR 17.0 MILLION VERSUS LOSS OF EUR 14.8 MILLION YEAR AGO\n* ON TRACK TO OBTAIN A CHMP OPINION IN Q4 OF 2018 FOR OUR LEAD PROGRAM ATIR101\n* FY OPERATING LOSS EUR 16.1 MILLION VERSUS LOSS OF EUR 11.4 MILLION YEAR AGO\n* IF POSITIVE, CHMP OPINION WOULD ENABLE AN APPROVAL FROM EUROPEAN COMMISSION IN Q1 OF 2019\n* CASH POSITION INCREASED TO EUR 29.6 MILLION AT YEAR-END 2017 COMPARED TO EUR 14.6 MILLION AT END OF 2016\n* POTENTIAL LAUNCH OF PROGRAM ATIR101 IN SELECTED COUNTRIES IN EUROPE STARTING IN H2 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-13T13:10:00.000+03:00",
    "crawled": "2018-04-14T13:35:27.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "kiadis",
        "pharma",
        "nv",
        "kiadis",
        "pharma",
        "announces",
        "annual",
        "result",
        "year",
        "ended",
        "december",
        "significantly",
        "strengthened",
        "cash",
        "position",
        "raised",
        "eur",
        "million",
        "equity",
        "debt",
        "gross",
        "including",
        "raise",
        "march",
        "filed",
        "marketing",
        "authorization",
        "application",
        "european",
        "medicine",
        "agency",
        "atir101",
        "blood",
        "cancer",
        "fy",
        "net",
        "loss",
        "eur",
        "million",
        "versus",
        "loss",
        "eur",
        "million",
        "year",
        "ago",
        "track",
        "obtain",
        "chmp",
        "opinion",
        "q4",
        "lead",
        "program",
        "atir101",
        "fy",
        "operating",
        "loss",
        "eur",
        "million",
        "versus",
        "loss",
        "eur",
        "million",
        "year",
        "ago",
        "positive",
        "chmp",
        "opinion",
        "would",
        "enable",
        "approval",
        "european",
        "commission",
        "q1",
        "cash",
        "position",
        "increased",
        "eur",
        "million",
        "compared",
        "eur",
        "million",
        "end",
        "potential",
        "launch",
        "program",
        "atir101",
        "selected",
        "country",
        "europe",
        "starting",
        "h2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}